BIO-key International, Inc. (BKYI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BKYI SEC filings page.
BIO-key International, Inc. (BKYI) reported $6.7M in revenue over the twelve months to Jun 30, 2026, down 3.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BIO-key’s reported profits mask an operating shortfall: cash generation remains negative while 2025 financing supplied $6.9M .
In FY2025, reported net income of$7.2M coexisted with operating cash flow of-$4.7M , so the bottom line did not translate into cash from the business. The gap indicates that non-operating items materially shape reported earnings while core operations continue consuming cash.
Gross margin remained
The current ratio recovered to 1.5x in FY2025 from 0.4x in FY2024, indicating improved short-term coverage. That improvement coincided with financing cash flow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BIO-key International, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BIO-key International, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 24/100.
BIO-key International, Inc.'s revenue declined 14.3% year-over-year, from $6.9M to $5.9M. This contraction results in a growth score of 7/100.
BIO-key International, Inc. has a moderate D/E ratio of 0.63. This balance of debt and equity financing earns a leverage score of 56/100.
BIO-key International, Inc.'s current ratio of 1.47 indicates adequate short-term liquidity, earning a score of 40/100. The company can meet its near-term obligations, though with limited headroom.
BIO-key International, Inc.'s operations used $4.7M of cash, and capex of $12K added to the outflow, for a free cash flow shortfall of $4.7M. This results in a cash flow score of 4/100.
BIO-key International, Inc. generates a 140.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 10/100. This is up from 114.0% the prior year.
BIO-key International, Inc. scores -24.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.0M) relative to total liabilities ($3.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BIO-key International, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, BIO-key International, Inc. used $0.65 of operating cash (-$4.7M OCF vs $7.2M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
BIO-key International, Inc. reported an operating loss of $6.8M against $61K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BIO-key International, Inc. generated $1.9M in revenue in Q2 2026. This represents an increase of 13.1% from the same quarter a year earlier. Against the prior quarter it is down 10.5%.
BIO-key International, Inc.'s EBITDA was -$455K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 53.7% from the same quarter a year earlier. Against the prior quarter it is down 423.6%.
BIO-key International, Inc. reported -$577K in net income in Q2 2026. This represents an increase of 50.6% from the same quarter a year earlier. Against the prior quarter it is down 181.3%.
Not reported for Q2 2026.
Cash & Balance Sheet
BIO-key International, Inc. recorded an outflow of $846K in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 4.1% from the same quarter a year earlier. Against the prior quarter it is down 136.2%.
BIO-key International, Inc. held $1.4M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
BIO-key International, Inc.'s gross margin was 87.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 14.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.7 percentage points.
BIO-key International, Inc.'s operating margin was -27.6% in Q2 2026, reflecting core business profitability. This is up 36.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.2 percentage points.
BIO-key International, Inc.'s net profit margin was -30.0% in Q2 2026, showing the share of revenue converted to profit. This is up 38.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.5 percentage points.
BIO-key International, Inc.'s ROE was -13.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.1 percentage points.
Capital Allocation
BIO-key International, Inc. invested $640K in research and development in Q2 2026. This represents an increase of 0.7% from the same quarter a year earlier. Against the prior quarter it is up 3.8%.
BIO-key International, Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
BKYI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M+13.1% | $2.1M+33.5% | $1.1M-25.9% | $1.5M-27.7% | $1.7M+48.7% | $1.6M-26.3% | $1.5M-19.9% | $2.1M+18.0% |
| Cost of Revenue | $246K-47.0% | $376K+34.6% | $271K+3.4% | $358K-23.0% | $464K+77.0% | $279K-6.7% | $262K-86.3% | $465K-68.5% |
| Gross Profit | $1.7M+35.8% | $1.8M+33.3% | $812K-32.3% | $1.2M-29.1% | $1.2M+40.2% | $1.3M-29.4% | $1.2M+1356.5% | $1.7M+393.3% |
| R&D Expenses | $640K+0.7% | $617K+3.5% | $694K+5.2% | $684K+4.8% | $636K+7.6% | $596K-1.9% | $660K+7.0% | $652K+23.1% |
| SG&A Expenses | $1.6M-7.0% | $1.3M-4.6% | $1.8M+1.2% | $1.4M-12.9% | $1.7M-13.5% | $1.4M-23.0% | $1.8M-17.7% | $1.6M-9.5% |
| Operating Income | -$529K+51.2% | -$158K+75.4% | -$4.2M-232.2% | -$892K-53.7% | -$1.1M+34.5% | -$641K-25.9% | -$1.3M+53.5% | -$580K+70.5% |
| EBITDA | -$455K+53.7% | -$87K+84.0% | -$4.4M-198.1% | -$815K-69.7% | -$983K+36.7% | -$543K-33.3% | -$1.5M+49.2% | -$480K+74.7% |
| Interest Expense | $27K+5.3% | $27K-24.3% | -$14K-120.8% | $13K-86.6% | $26K+187.7% | $36K+2548.2% | $67K+13.7% | $99K+115.9% |
| Income Tax | $0 | $0 | $17K+171.7% | $0 | $0 | $0 | -$23K+91.7% | $0+100.0% |
| Net Income | -$577K+50.6% | -$205K+72.2% | $10.0M+38.9% | -$965K-30.6% | -$1.2M+30.0% | -$737K-44.3% | $7.2M-50.3% | -$739K+59.8% |
| EPS (Basic) | -$0.56+72.1% | -$0.20+87.3% | -$10.27-2467.5% | -$0.15+61.5% | -$2.01-101.0% | -$1.57-390.6% | -$0.40+91.0% | -$0.39+87.9% |
Not reported in any period shown, so not listed: EPS (Diluted), Diluted Shares (Avg).
BKYI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.5M-28.8% | $8.2M-27.1% | $8.3M-3.6% | $10.1M+58.0% | $10.5M+119.1% | $11.2M+168.3% | $8.6M+90.7% | $6.4M-34.4% |
| Current Assets | $3.8M-5.7% | $4.5M-2.3% | $4.5M+140.5% | $3.7M-17.7% | $4.0M+33.9% | $4.6M+102.3% | $1.9M-28.0% | $4.6M+13.2% |
| Cash & Equivalents | $1.4M-39.4% | $2.2M-28.3% | $2.7M+515.8% | $2.0M+13.3% | $2.3M+80.5% | $3.1M+353.9% | $438K-14.4% | $1.8M+486.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $376K+18.0% | $338K-5.4% | $371K-2.0% | $394K+1.9% | $319K-26.5% | $358K-18.7% | $378K-15.1% | $387K-78.4% |
| Accounts Receivable | $1.7M+76.0% | $1.6M+95.9% | $1.2M+70.0% | $960K-50.3% | $984K+8.8% | $803K+14.5% | $718K-40.2% | $1.9M+28.8% |
| Long-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $5.0M | $5.0M | $5.0M | $5.0M | $0 |
| Total Liabilities | $3.1M-14.1% | $3.3M-10.7% | $3.2M-34.0% | $4.1M-35.1% | $3.7M-37.4% | $3.7M+0.6% | $4.8M+40.3% | $6.3M-38.8% |
| Current Liabilities | $3.0M-14.7% | $3.2M-7.9% | $3.1M-32.0% | $3.0M-49.5% | $3.5M-36.6% | $3.5M+4.5% | $4.6M+41.7% | $5.9M-2.6% |
| Non-Current Liabilities | $135K+1.9% | $75K-60.9% | $100K-65.4% | $1.1M+178.4% | $132K-52.8% | $191K-39.7% | $290K+20.8% | $397K-2.5% |
| Long-Term Debt | N/A | N/A | N/A | N/A | $0-100.0% | $12K-92.2% | $45K-76.3% | $84K-62.1% |
| Total Equity | $4.3M-36.7% | $4.9M-35.0% | $5.1M+35.4% | $6.0M+4443.7% | $6.9M+748.7% | $7.5M+1305.0% | $3.8M+254.7% | $133K+127.4% |
| Retained Earnings | -$137.2M-4.6% | -$136.7M-5.1% | -$136.5M-5.5% | -$132.2M-3.3% | -$131.2M-3.2% | -$130.0M-3.6% | -$129.3M-3.4% | -$127.9M-4.3% |
Not reported in any period shown, so not listed: Goodwill.
BKYI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$846K+3.9% | -$358K+57.1% | -$1.8M-255.8% | -$1.1M+12.0% | -$880K+38.1% | -$835K-381.2% | -$515K+66.4% | -$1.3M-665.3% |
| Depreciation & Amortization | $74K-26.2% | $71K-27.8% | -$192K+8.5% | $78K-22.7% | $100K+0.3% | $98K-3.7% | -$209K-15.6% | $100K+49.0% |
| Stock-Based Compensation | $43K+95.3% | $41K-22.4% | N/A | $32K-52.1% | $22K-55.2% | $52K-7.6% | N/A | $66K-37.2% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $5K-53.6% | $1K-93.7% | $1K | $5K+144.5% | -$10K+900.0% | $21K |
| Free Cash Flow | -$846K+4.1% | -$358K+57.4% | -$1.8M-249.9% | -$1.1M+13.3% | -$881K+38.0% | -$840K-384.5% | -$525K+65.8% | -$1.3M-678.0% |
| Investing Cash Flow | $0+100.0% | $0+100.0% | -$5K-146.4% | -$1K+93.7% | -$1K | -$5K-144.5% | $10K+1100.0% | -$21K |
| Financing Cash Flow | $8K+121.4% | -$38K-101.1% | $2.5M+394.7% | $963K-44.9% | -$36K-101.8% | $3.5M+6648.8% | -$834K-153.5% | $1.7M+2204.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BKYI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.2%+14.5pp | 82.5%-0.1pp | 75.0%-7.1pp | 76.9%-1.4pp | 72.7%-4.4pp | 82.6%-3.7pp | 82.1%+87.3pp | 78.3%+59.6pp |
| Operating Margin | -27.6%+36.3pp | -7.3%+32.5pp | -388.5% | -57.6%-30.5pp | -63.9% | -39.9%-16.5pp | -86.7% | -27.1% |
| Net Margin | -30.0%+38.8pp | -9.6%+36.3pp | 925.2% | -62.3%-27.8pp | -68.8% | -45.8%-22.4pp | 493.5% | -34.4% |
| Return on Equity | -13.3%+3.7pp | -4.2%+5.6pp | 196.3%+5.0pp | -16.0%+539.5pp | -17.0% | -9.8%+85.5pp | 191.3%-1174.7pp | -555.4% |
| Return on Assets | -7.7%+3.4pp | -2.5%+4.1pp | 120.8%+37.0pp | -9.5%+2.0pp | -11.1%+23.6pp | -6.6%+5.6pp | 83.8%-237.9pp | -11.6%+7.3pp |
| Current Ratio | 1.26+0.1x | 1.41+0.1x | 1.47+1.1x | 1.26+0.5x | 1.14+0.6x | 1.32+0.6x | 0.41-0.4x | 0.78+0.1x |
| Debt-to-Equity | 0.73+0.7x | 0.67+0.7x | 0.63+0.6x | 0.670.0x | 0.00 | 0.00-0.3x | 0.01-0.2x | 0.63 |
| Asset Turnover | 0.26+0.1x | 0.26+0.1x | 0.130.0x | 0.15-0.2x | 0.16-0.1x | 0.14-0.4x | 0.17-0.2x | 0.34+0.1x |
| FCF Margin | -44.0%+7.9pp | -16.7%+35.6pp | -169.3% | -72.5%-12.1pp | -51.9% | -52.3%-65.8pp | -35.9%+48.1pp | -60.5%-51.3pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BIO-key International, Inc. BKYI | FY2025 | $5.9M | $7.2M | N/A | $3.0M | 24/100 |
| Iveda Solutions, Inc. IVDA | FY2025 | $5.3M | -$3.2M | -60.6% | $3.6M | 55/100 |
| SU Group Holdings Limited SUGP | FY2025 | $24.7M | -$2.4M | -9.6% | $665K | 43/100 |
| VerifyMe, Inc. VRME | FY2025 | $16.4M | -$4.9M | -29.9% | $11.8M | 38/100 |
| Guardforce AI Co., Limited GFAI | FY2025 | $35.2M | -$6.6M | -18.9% | $9.7M | 32/100 |
| SuperCom, Ltd SPCB | FY2025 | $27.9M | $3.7M | 13.4% | $59.1M | 47/100 |
Where BIO-key International, Inc. Ranks
Frequently Asked Questions
What is BIO-key International, Inc.'s annual revenue?
BIO-key International, Inc. (BKYI) reported $5.9M in total revenue for fiscal year 2025. This represents a -14.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BIO-key International, Inc.'s revenue growing?
BIO-key International, Inc. (BKYI) revenue declined by 14.3% year-over-year, from $6.9M to $5.9M in fiscal year 2025.
Is BIO-key International, Inc. profitable?
Yes, BIO-key International, Inc. (BKYI) reported a net income of $7.2M in fiscal year 2025.
What is BIO-key International, Inc.'s EBITDA?
BIO-key International, Inc. (BKYI) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BIO-key International, Inc.'s gross margin?
BIO-key International, Inc. (BKYI) had a gross margin of 76.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BIO-key International, Inc.'s return on equity (ROE)?
BIO-key International, Inc. (BKYI) has a return on equity of 140.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BIO-key International, Inc.'s free cash flow?
BIO-key International, Inc. (BKYI) recorded an outflow of $4.7M in free cash flow during fiscal year 2025. This represents a -59.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BIO-key International, Inc.'s operating cash flow?
BIO-key International, Inc. (BKYI) recorded an outflow of $4.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BIO-key International, Inc.'s total assets?
BIO-key International, Inc. (BKYI) had $8.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BIO-key International, Inc.'s capital expenditures?
BIO-key International, Inc. (BKYI) invested $12K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BIO-key International, Inc. spend on research and development?
BIO-key International, Inc. (BKYI) invested $2.6M in research and development during fiscal year 2025.
What is BIO-key International, Inc.'s current ratio?
BIO-key International, Inc. (BKYI) had a current ratio of 1.47 as of fiscal year 2025, which is considered adequate.
What is BIO-key International, Inc.'s debt-to-equity ratio?
BIO-key International, Inc. (BKYI) had a debt-to-equity ratio of 0.63 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BIO-key International, Inc.'s return on assets (ROA)?
BIO-key International, Inc. (BKYI) had a return on assets of 86.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BIO-key International, Inc.'s P/E ratio?
BIO-key International, Inc. (BKYI) trades at 0.4x earnings, its market capitalization divided by net income of $8.3M net income, trailing 12 months to June 30, 2026. The market capitalization is $3.0M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BIO-key International, Inc.'s price-to-sales ratio?
BIO-key International, Inc. (BKYI) trades at 0.5x sales, its market capitalization divided by revenue of $6.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $3.0M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does BIO-key International, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BIO-key International, Inc. (BKYI) held $2.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.7M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is BIO-key International, Inc.'s Altman Z-Score?
BIO-key International, Inc. (BKYI) has an Altman Z-Score of -24.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BIO-key International, Inc.'s Piotroski F-Score?
BIO-key International, Inc. (BKYI) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BIO-key International, Inc.'s earnings high quality?
For every $1 of reported earnings, BIO-key International, Inc. (BKYI) used $0.65 of operating cash (-$4.7M OCF vs $7.2M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BIO-key International, Inc. cover its interest payments?
BIO-key International, Inc. (BKYI) reported an operating loss of $6.8M against $61K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is BIO-key International, Inc.?
BIO-key International, Inc. (BKYI) scores 24 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.